Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.

JAMA oncology·2026

Same author

ASO Visual Abstract: From Clinical Trial Awareness to Practice-Factors Associated with Intent to Omit Axillary Surgery Based on the SOUND Clinical Trial.

Annals of surgical oncology·2026

Same author

Longitudinal multi-platform profiling reveals temporal dynamics of HER2, TROP2, PD-L1 and tumor-infiltrating lymphocytes in triple-negative breast cancer.

medRxiv : the preprint server for health sciences·2026

Same author

Multidisciplinary clinics in cancer-models, metrics, and meaning: a review.

The oncologist·2026

Same author

Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort.

JNCI cancer spectrum·2026

Same author

ASO Visual Abstract: Receipt of Combined Axillary Dissection and Nodal Irradiation Varies by Age.

Annals of surgical oncology·2026

Same journal

HIV Apheresis Tags (HIVAT) Aided Elimination of Viremia.

Molecular and cellular therapies·2019

Same journal

HIV Universal Vaccine.

Molecular and cellular therapies·2019

Same journal

Albumin-based drug delivery: harnessing nature to cure disease.

Molecular and cellular therapies·2016

Same journal

The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia.

Molecular and cellular therapies·2016

Same journal

Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules.

Molecular and cellular therapies·2016

Same journal

Proteomic analysis of extracellular vesicles from medullospheres reveals a role for iron in the cancer progression of medulloblastoma.

Molecular and cellular therapies·2015

See all related articles

Search research articles

Related Experiment Video

Updated: Apr 11, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Adoptive T-cell therapy for Leukemia.

Haven R Garber¹, Asma Mirza¹, Elizabeth A Mittendorf²

¹Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center Houston, Houston, 77030 Texas.

Molecular and Cellular Therapies

|June 10, 2015

Summary

This summary is machine-generated.

Adoptive cellular therapy (ACT) shows promise for leukemia treatment by engineering T-cells to target specific leukemia antigens. This approach aims to improve efficacy and reduce risks associated with traditional stem cell transplants.

Keywords:

Adoptive cellular therapy Chimeric antigen receptor Engineered T-cell Immunotherapy Leukemia Stem cell transplant T-cell Tumor antigen

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Apr 11, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Area of Science:

Immunology
Oncology
Cell Therapy

Background:

Allogeneic stem cell transplantation (alloSCT) is a potent cancer immunotherapy for leukemia.
Graft-versus-host disease (GvHD) limits alloSCT efficacy.
Targeting specific leukemia antigens can enhance graft-versus-leukemia (GvL) effects.

Purpose of the Study:

To review promising leukemia antigens and novel adoptive cellular immunotherapy strategies.
To summarize data on ACT for lymphoid and myeloid leukemias.
To highlight advancements in T-cell engineering for cancer treatment.

Main Methods:

Review of preclinical studies and clinical trials in adoptive cellular therapy for leukemia.
Focus on engineered T-cells, including chimeric antigen receptor (CAR) T-cells.
Discussion of identified leukemia antigens and their targeting strategies.

Main Results:

Engineered T-cells demonstrate potent leukemia cell lysis and eradication in preclinical models.
Anti-CD19 CAR T-cells show recent clinical success in acute lymphoblastic and chronic lymphocytic leukemias.
Numerous clinical trials are underway, translating research into patient care.

Conclusions:

Targeting specific leukemia antigens with engineered T-cells offers a refined approach to immunotherapy.
Adoptive cellular therapy holds significant potential for treating hematologic malignancies.
Continued research and clinical trials are crucial for advancing leukemia treatment.